(Q36893549)

16 August 2017

1 reference

title

Management of nonmelanoma skin cancer in 2007. (English)

1 reference

16 August 2017

1 reference

Julie A Neville

1

1 reference

16 August 2017

Erin Welch

series ordinal

2

1 reference

16 August 2017

David J Leffell

series ordinal

3

1 reference

16 August 2017

publication date

1 August 2007

1 reference

Nature Clinical Practice Oncology

16 August 2017

published in

1 reference

16 August 2017

volume

4

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

462-469

1 reference

Skin cancer is among the most costly of all cancers to treat for the Medicare population

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Nonmelanoma skin cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

The meaning of surgical margins

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Mohs micrographic surgery

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

A systematic review of treatment modalities for primary basal cell carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Radiotherapy in the treatment of dermatologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Recurrence Rates of Treated Basal Cell Carcinomas: Part 4: X-Ray Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0883

1 reference

7 January 2021

Surgical management of cutaneous malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Curettage, electrosurgery and skin cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Curettage-electrodesiccation treatment of basal cell carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Medical therapies for non-melanoma skin cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Topical chemotherapy with 5-fluorouracil. A review

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Nonmelanoma skin cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Imiquimod 5% cream in the treatment of Bowen's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0883

7 January 2021

Identifiers

DOI

10.1038/NCPONC0883

1 reference

Dimensions Publication ID

16 August 2017

1035867075

0 references

1 reference